| ORIGINAL ARTICLE |
|
| Year : 2013 | Volume
: 17
| Issue : 8 | Page : 435-436 |
|
|
Clinical experience with biphasic insulin aspart in people with type 2 diabetes: Results from the Libya cohort of the A 1 chieve study
Issam M Hajjaji1, Ibrahim Sherif2, Aisha Elazrag3, Suhair Jaber4, Praful N Chakkarwar5, Salem Eltabal6
1 Diabetic Centre, Benghazi, Libya
2 Alafia Clinic, Benghazi, Libya
3 Tripoli Medical Centre, Benghazi, Libya
4 Benghazi, Libya
5 Department of CMR, Novo Nordisk Pharma Gulf FZ-LLC, Dubai, United Arab Emirates
6 Department of Endocrinology Division and Medicine, Benghazi Medical Treatment, Benghazi, Libya
Correspondence Address:
Praful N Chakkarwar
Novo Nordisk Pharma Gulf FZ-LLC, Dubai Healthcare City Building 64, Block A & B, P.O. Box 505052 Dubai
United Arab Emirates
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2230-8210.122062
|
|
|
Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents. Materials and Methods: Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled in biphasic insulin aspart sub group from Libya. Results: A total of 179 patients were enrolled in the biphasic insulin aspart subgroup. All the patients were prior insulin users. At baseline glycaemic control was poor (mean HbA 1 c: 9.3%). After 24 weeks of treatment there was an improvement in HbA 1 c (−0.9%). Hypoglycaemic events reduced from 7.2 events/patient-year to 3.7 events/patient-year in 24 weeks. SADRs did not occur in any of the study patients. Conclusion: Starting or switching to biphasic insulin aspart was associated with improvement in glycaemic control with a low rate of hypoglycaemia. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
